These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 35416981)

  • 1. Exendin-(9-39) Effects on Glucose and Insulin in Children With Congenital Hyperinsulinism During Fasting and During a Meal and a Protein Challenge.
    Stefanovski D; Vajravelu ME; Givler S; De León DD
    Diabetes Care; 2022 Jun; 45(6):1381-1390. PubMed ID: 35416981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GLP-1 receptor antagonist exendin-(9-39) elevates fasting blood glucose levels in congenital hyperinsulinism owing to inactivating mutations in the ATP-sensitive K+ channel.
    Calabria AC; Li C; Gallagher PR; Stanley CA; De León DD
    Diabetes; 2012 Oct; 61(10):2585-91. PubMed ID: 22855730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exendin-(9-39) corrects fasting hypoglycemia in SUR-1-/- mice by lowering cAMP in pancreatic beta-cells and inhibiting insulin secretion.
    De León DD; Li C; Delson MI; Matschinsky FM; Stanley CA; Stoffers DA
    J Biol Chem; 2008 Sep; 283(38):25786-93. PubMed ID: 18635551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics of exendin-(9-39) and clinical dose selection in patients with congenital hyperinsulinism.
    Ng CM; Tang F; Seeholzer SH; Zou Y; De León DD
    Br J Clin Pharmacol; 2018 Mar; 84(3):520-532. PubMed ID: 29077992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel Hypoglycemia Phenotype in Congenital Hyperinsulinism Due to Dominant Mutations of Uncoupling Protein 2.
    Ferrara CT; Boodhansingh KE; Paradies E; Fiermonte G; Steinkrauss LJ; Topor LS; Quintos JB; Ganguly A; De Leon DD; Palmieri F; Stanley CA
    J Clin Endocrinol Metab; 2017 Mar; 102(3):942-949. PubMed ID: 27967291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppression of insulin oversecretion by subcutaneous recombinant human insulin-like growth factor I in children with congenital hyperinsulinism due to defective beta-cell sulfonylurea receptor.
    Katz LE; Ferry RJ; Stanley CA; Collett-Solberg PF; Baker L; Cohen P
    J Clin Endocrinol Metab; 1999 Sep; 84(9):3117-24. PubMed ID: 10487673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein-sensitive and fasting hypoglycemia in children with the hyperinsulinism/hyperammonemia syndrome.
    Hsu BY; Kelly A; Thornton PS; Greenberg CR; Dilling LA; Stanley CA
    J Pediatr; 2001 Mar; 138(3):383-9. PubMed ID: 11241047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Potential Role for Endogenous Glucagon in Preventing Post-Bariatric Hypoglycemia.
    Lobato CB; Pereira SS; Guimarães M; Hartmann B; Wewer Albrechtsen NJ; Hilsted L; Holst JJ; Nora M; Monteiro MP
    Front Endocrinol (Lausanne); 2020; 11():608248. PubMed ID: 33424773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postprandial Hypoglycemia in Children after Gastric Surgery: Clinical Characterization and Pathophysiology.
    Calabria AC; Charles L; Givler S; De León DD
    Horm Res Paediatr; 2016; 85(2):140-6. PubMed ID: 26694545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GIP and GLP-1 Receptor Antagonism During a Meal in Healthy Individuals.
    Gasbjerg LS; Helsted MM; Hartmann B; Sparre-Ulrich AH; Veedfald S; Stensen S; Lanng AR; Bergmann NC; Christensen MB; Vilsbøll T; Holst JJ; Rosenkilde MM; Knop FK
    J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 32077470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucose metabolism in 105 children and adolescents after pancreatectomy for congenital hyperinsulinism.
    Beltrand J; Caquard M; Arnoux JB; Laborde K; Velho G; Verkarre V; Rahier J; Brunelle F; Nihoul-Fékété C; Saudubray JM; Robert JJ; de Lonlay P
    Diabetes Care; 2012 Feb; 35(2):198-203. PubMed ID: 22190679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Use of Lanreotide in the Treatment of Congenital Hyperinsulinism.
    Cuff H; Lord K; Ballester L; Scully T; Stewart N; De Leon DD
    J Clin Endocrinol Metab; 2022 Jul; 107(8):e3115-e3120. PubMed ID: 35587448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes.
    Lund SS; Tarnow L; Frandsen M; Smidt UM; Pedersen O; Parving HH; Vaag AA
    Eur J Endocrinol; 2008 Jan; 158(1):35-46. PubMed ID: 18166815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomarkers of Insulin for the Diagnosis of Hyperinsulinemic Hypoglycemia in Infants and Children.
    Ferrara C; Patel P; Becker S; Stanley CA; Kelly A
    J Pediatr; 2016 Jan; 168():212-219. PubMed ID: 26490124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers.
    Edwards CM; Stanley SA; Davis R; Brynes AE; Frost GS; Seal LJ; Ghatei MA; Bloom SR
    Am J Physiol Endocrinol Metab; 2001 Jul; 281(1):E155-61. PubMed ID: 11404233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of GLP-1 in the postprandial effects of acarbose in type 2 diabetes.
    Dalsgaard NB; Gasbjerg LS; Hansen LS; Hansen NL; Stensen S; Hartmann B; Rehfeld JF; Holst JJ; Vilsbøll T; Knop FK
    Eur J Endocrinol; 2021 Mar; 184(3):383-394. PubMed ID: 33449919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-Gastric Bypass Hyperinsulinemic Hypoglycemia: Fructose is a Carbohydrate Which Can Be Safely Consumed.
    Bantle AE; Wang Q; Bantle JP
    J Clin Endocrinol Metab; 2015 Aug; 100(8):3097-102. PubMed ID: 26037514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dominant form of congenital hyperinsulinism maps to HK1 region on 10q.
    Pinney SE; Ganapathy K; Bradfield J; Stokes D; Sasson A; Mackiewicz K; Boodhansingh K; Hughes N; Becker S; Givler S; Macmullen C; Monos D; Ganguly A; Hakonarson H; Stanley CA
    Horm Res Paediatr; 2013; 80(1):18-27. PubMed ID: 23859901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes.
    Juhl CB; Hollingdal M; Sturis J; Jakobsen G; Agersø H; Veldhuis J; Pørksen N; Schmitz O
    Diabetes; 2002 Feb; 51(2):424-9. PubMed ID: 11812750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of glucagon response on postprandial hyperglycemia in men with impaired glucose tolerance and type 2 diabetes mellitus.
    Henkel E; Menschikowski M; Koehler C; Leonhardt W; Hanefeld M
    Metabolism; 2005 Sep; 54(9):1168-73. PubMed ID: 16125528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.